← Return to ARSI PR wars: Nubeqa (Bayer) vs Erleada (J & J) lawsuit

Discussion
northoftheborder avatar

ARSI PR wars: Nubeqa (Bayer) vs Erleada (J & J) lawsuit

Prostate Cancer | Last Active: Mar 4 5:17am | Replies (36)
Comment receiving replies
Profile picture for northoftheborder @northoftheborder

Well, we did have the retrospective head-to-head RWA on side-effects that I linked to earlier in the thread, but yes, a full-scale, head-to-head phase 4 trial would cost a lot of money.

I expect we'll see Enzalutamide replace Abieraterone as the insurers' default/inexpensive option as soon as there are generics available, and Abiraterone will start to fall off oncologists' radars.

There's really little/no downside in moving from Abieraterone to a -lutamide, and the huge upside of no longer forcing patients to take a steroid (with its own, extr collection of nasty side-effects).

Jump to this post

Replies to "Well, we did have the retrospective head-to-head RWA on side-effects that I linked to earlier in..."
Jeff Marchi | @jeffmarc | Mar 2 4:49pm

@northoftheborder
There is some logic to starting with abiraterone.

If you get on abiraterone first It does give you a couple more years at least before you move on to a lutamide. As long as it doesn’t fail you (PSA rises) then moving to a lutamide Extends the amount of total time you can be on an ARPI.

If abiraterone Fails you and you try to move onto a lutamide The odds are not good that it will work, Around 15%.

If you start on a lutamide and it fails you Then you cannot usually move onto to abiraterone.

I got 2.5 years out of abiraterone, and now almost 3 out of Darolutamide. If I had started on a lutamide It very likely would’ve failed me within five years.

Just something more to think about

VIEW AND REPLY